Roth Capital analyst Jerry Isaacson initiated Altimmune with a Buy rating and $8.30 price target. In a research note to investors, Isaacson says the Spitfire Pharma deal is "very good" for Altimmune, both in terms of the "very large" market opportunity in nonalcoholic steatohepatits and that the company was able to complete the deal with stock, and views ALT-801 as the primary driver of value for the company. The analyst assumes approval for ALT-801 in NASH in 2027 with pricing starting at $4,000 annually per patient, which is in line with current expectations for NASH treatments.